Last reviewed · How we verify

OXALIPLATIN — Competitive Intelligence Brief

OXALIPLATIN (OXALIPLATIN) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based Drug [EPC].

marketed Platinum-based Drug [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

OXALIPLATIN (OXALIPLATIN).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
OXALIPLATIN TARGET OXALIPLATIN marketed Platinum-based Drug [EPC] 2002-01-01
CISPLATIN CISPLATIN marketed Platinum-based Drug [EPC] 1978-01-01
Platinol-Aq cisplatin Pfizer marketed Platinum-based Drug [EPC] D(3) dopamine receptor 1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based Drug [EPC] class)

  1. · 2 drugs in this class
  2. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OXALIPLATIN — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl414804. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: